Conversion from Cyclosporine to Tacrolimus in Renal Allograft Recipients with Chronic Allograft Nephropathy: A Prospective Single Center Study

Shu-ming Ji,Lei-shi Li,Jin-song Chen,Guo-zhu Sha,Zhi-hong Liu

DOI: https://doi.org/10.3969/j.issn.1008-8199.2011.01.008

2011-01-01

Abstract:Objective This study evaluated the efficacy and safety of tacrolimus(FK506) as secondary intervention in cyclosporine A(CsA) treated renal transplantation patients with chronic allograft nephropathy(CAN).Methods Sixty-one patients who received a cadeveric renal transplantation in our unit more than 12 months prior to study enrollment and who were being treated with CsA-based immunosuppressive treatment were included,all patients received allograft biopsy and were diagnosed as CAN according to Banff criteria.Patients were differentiated according to following regimen.Patients were either converted to FK506 group(n=31) or remained on their initial CsA-based immunosuppression(CsA group,n=30).An important effectiveness index is the rate of decline of renal function before and after the FK506 conversion,calculated by curve fitting and regression analysis with reciprocal SCr as Y-axis and time as X-axis.Therapeutic effectiveness is defined as improvement or stabilization of renal function.Improvement: slope of serum creatinine less than-5%;Stabilization: slope of serum creatinine between -5% and 5%;Deterioration of renal function: slope of serum creatinine larger than 5%.Results Trough TC,TG and LDL levels remained unchanged in CsA group while statistically reduced in FK506 group.Renal function was markedly improved in FK506 group.Among the twenty-four patients with improvement in the rate of decline of renal function,twenty patients(64.5%) had their regression lines become positive and four patients(12.9%) had their regression lines become less negative.Seven patients(22.6%) had increased rate of decline in renal function with their regression lines becoming more negative.The clinical efficiency after the FK506 conversion for 31 patients was compared with the pathological degree of allograft nephropathy before the conversion,and the lighter the pathological degree was,the higher the improvement rate of renal function was,and vice versa.Graft survival rate was significantly increased in FK506 group(93.5% vs 76.7%,P0.01) follow-up one year.The incidence rates of hypertension,hypertrichosis,gum hypertrophy,liver disfunction,and CMV pneumonia in FK506 group were markedly lower than those in CsA group,63.8% vs 84.6%(P0.01),22.4% vs 53.8%(P0.01),8.6% vs 51.3%(P0.01),6.5% vs 16.7%(P0.01) and 6.5% vs 10.0%(P0.05),respectively.Conclusion FK506 treatment markedly improved abnormality in lipid profile and graft renal function post-transplantation.Conversion from a CsA-based regimen to a tacrolimus-based regimen was an effective alterative for salvage of patients with abnormal graft renal function induced by CAN.